Contrasting Turnstone Biologics (NASDAQ:TSBX) & AlloVir (NASDAQ:ALVR)

Turnstone Biologics (NASDAQ:TSBX) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

Insider & Institutional Ownership

52.5% of Turnstone Biologics shares are owned by institutional investors. Comparatively, 66.1% of AlloVir shares are owned by institutional investors. 32.1% of Turnstone Biologics shares are owned by company insiders. Comparatively, 32.1% of AlloVir shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Turnstone Biologics and AlloVir”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turnstone Biologics	$19.31 million	0.61	-$55.20 million	($3.24)	-0.16
AlloVir	N/A	N/A	-$190.42 million	($0.88)	-0.51

Turnstone Biologics has higher revenue and earnings than AlloVir. AlloVir is trading at a lower price-to-earnings ratio than Turnstone Biologics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and target prices for Turnstone Biologics and AlloVir, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turnstone Biologics	1	0	1	0	2.00
AlloVir	0	0	0	0	0.00

Turnstone Biologics presently has a consensus target price of $2.13, suggesting a potential upside of 315.85%. Given Turnstone Biologics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Turnstone Biologics is more favorable than AlloVir.

Risk & Volatility

Turnstone Biologics has a beta of 2.14, indicating that its stock price is 114% more volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500.

Profitability

This table compares Turnstone Biologics and AlloVir’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Turnstone Biologics	N/A	-105.99%	-87.27%
AlloVir	N/A	-71.03%	-61.27%

Summary

Turnstone Biologics beats AlloVir on 8 of the 12 factors compared between the two stocks.

About Turnstone Biologics

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.

About AlloVir

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.